| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
45,560,000 |
| Market
Cap: |
12.06(M) |
| Last
Volume: |
1,167,076 |
Avg
Vol: |
635,303 |
| 52
Week Range: |
$0.2646 - $0.2646 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
129,000 |
129,000 |
| Total Buy Value |
$0 |
$0 |
$205,884 |
$205,884 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
168 |
168 |
168 |
168 |
| Total Sell Value |
$314 |
$314 |
$314 |
$314 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2025-09-25 |
2025-06-24 |
2024-12-24 |
2023-12-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bashan Dror |
PRESIDENT AND CEO |
• • – |
2025-12-19 |
4 |
B |
$1.81 |
$101,360 |
D/D |
56,000 |
188,516 |
0.01 |
- |
|
| Bar-Shalev Amos |
|
– • – |
2025-11-18 |
4 |
S |
$1.87 |
$314 |
D/D |
(168) |
0 |
|
- |
|
| Bar-Shalev Amos |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Elze Christian |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Ben Zvi Shmuel |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Bashan Dror |
PRESIDENT AND CEO |
• • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
195,000 |
2,344,418 |
|
- |
|
| Forster Eliot |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Naos Yaron |
Sr. VP, Operations |
• – – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
225,817 |
|
- |
|
| Schwartz Aharon |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Melincoff Gwen A |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Boudes Pol F |
|
– • – |
2025-09-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,500 |
7,500 |
|
- |
|
| Schwartz Aharon |
|
– • – |
2025-06-10 |
4 |
B |
$1.60 |
$205,884 |
D/D |
129,000 |
303,000 |
0.01 |
- |
|
| Rubin Eyal |
Sr. VP and CFO |
• – – |
2024-09-23 |
4/A |
A |
$0.00 |
$0 |
I/I |
90,909 |
660,909 |
|
- |
|
| Rubin Eyal |
Sr. VP and CFO |
• – – |
2024-09-23 |
4 |
A |
$0.00 |
$0 |
I/I |
99,010 |
669,010 |
|
- |
|
| Bashan Dror |
PRESIDENT AND CEO |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
263,960 |
2,149,418 |
|
- |
|
| Bashan Dror |
PRESIDENT AND CEO |
• • – |
2023-10-19 |
4 |
B |
$1.40 |
$90,484 |
D/D |
64,516 |
132,516 |
0.01 |
- |
|
| Bashan Dror |
President and CEO |
• • – |
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
800,000 |
1,885,458 |
|
- |
|
| Naos Yaron |
Sr. VP, Operations |
• – – |
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
187,344 |
200,817 |
|
- |
|
| Rubin Eyal |
Sr. VP and CFO |
• – – |
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
201,903 |
570,000 |
|
- |
|
| Hayon Yael |
VP, Research & Development |
• – – |
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
35,115 |
35,115 |
|
- |
|
| Schwartz Aharon |
Director |
– • – |
2023-01-03 |
4 |
B |
$1.42 |
$155,815 |
D/D |
110,000 |
174,000 |
2.39 |
- |
|
| Bashan Dror |
President and CEO |
• • – |
2022-04-11 |
4 |
B |
$1.50 |
$102,000 |
D/D |
68,000 |
68,000 |
2.81 |
- |
|
| Rubin Eyal |
Sr. VP and CFO |
• – – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
121,951 |
368,097 |
|
- |
|
| Bashan Dror |
President and CEO |
• • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
637,531 |
1,085,458 |
|
- |
|
| Oren Dan |
10% Owner |
– – • |
2021-06-03 |
4 |
S |
$2.25 |
$1,932,304 |
D/D |
(857,506) |
3,637,314 |
|
- |
|
34 Records found
|
|
Page 1 of 2 |
|
|
